Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
12 2019
Historique:
received: 13 04 2019
revised: 25 06 2019
accepted: 27 06 2019
pubmed: 26 8 2019
medline: 26 5 2020
entrez: 26 8 2019
Statut: ppublish

Résumé

There has been a long-standing debate regarding the efficacy of single fraction radiotherapy (SFRT) compared to multiple fraction radiotherapy (MFRT); many systematic reviews and meta-analyses have been conducted to resolve the debate and suggested SFRT is equally as effective as MFRT. Given the adequate amalgamated sample size that exists, it is difficult to appreciate the need for further RCTs. The aim of this paper was to conduct a cumulative meta-analysis to determine whether further trials will be of value to the meta-conclusion. This paper also assessed publication quality. A total of 29 studies were used in our meta-analysis. Comprehensive Meta-Analysis (Version 3) by Biostat was used to conduct a cumulative meta-analysis. The Cochrane Risk of Bias assessment tool was employed to assess study quality of the included RCTs. Funnel plots were generated using Review Manager (RevMan 5.3) by Cochrane IMS, to visually assess for publication bias. All but one endpoint, overall response rates in assessable patients, maintained the same meta-conclusion over publication time; published studies did not change the amalgamated scientific conclusion of existing literature. Additional studies have simply confirmed pre-existing conclusions and refined the point estimate of the efficacy estimate. The majority of included studies have low risk of bias. In conclusion, the meta-conclusion has remained consistent over time - SFRT is equally as efficacious as MFRT. Recent studies have had little impact on the overall conclusion, and given the vast amount of resources to execute a randomized trial, future resources should not be used to repeat these studies, and can be better allocated to test other hypotheses.

Identifiants

pubmed: 31445837
pii: S0167-8140(19)32978-0
doi: 10.1016/j.radonc.2019.06.037
pii:
doi:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-61

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Ronald Chow (R)

London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, London, Canada; Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada. Electronic address: rchow48@uwo.ca.

Peter Hoskin (P)

Mount Vernon Hospital, London, United Kingdom; University of Manchester, United Kingdom.

Steven E Schild (SE)

Mayo Clinic, Scottsdale, USA.

Srinivas Raman (S)

British Columbia Cancer Agency Vancouver Centre, Canada.

James Im (J)

London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, London, Canada.

Daniel Zhang (D)

London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, London, Canada.

Stephanie Chan (S)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada.

Nicholas Chiu (N)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada.

Leonard Chiu (L)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada.

Henry Lam (H)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada.

Edward Chow (E)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada.

Michael Lock (M)

London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, London, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH